BG
Beatriz J. Grinsztejn
Elite in HIV/AIDS
Check Beatriz J. Grinsztejn's experience treating your condition:
About Beatriz J. Grinsztejn

Beatriz Grinsztejn practices in Rio De Janeiro, Brazil. Grinsztejn is rated as an Elite expert by MediFind in the treatment of HIV/AIDS. They are also highly rated in 18 other conditions, according to our data. Their top areas of expertise are HIV/AIDS, Chagas Disease, Adult T-Cell Leukemia, AIDS Dysmorphic Syndrome, and Liver Transplant.

Their clinical research consists of co-authoring 383 peer reviewed articles and participating in 14 clinical trials in the past 15 years. In particular, they have co-authored 351 articles and participated in 12 clinical trials in the study of HIV/AIDS.

Locations
Instituto Nacional De Infectologia Evandro Chagas/ Fiocruz, Rio De Janeiro, 21040360, BR
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Plasma for Early Treatment of COVID-19
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.
An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)
Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy in HIV-infected Women
View 11 Less Clinical Trials -

Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more